Customers for Life?

Customers for Life?

Up next

Investors Shoot for the Moon

Description: The quantum computing space needs to make progress on error correction before quantum computers are useful, and in the past week, both Alphabet and Quantinuum have made announcements regarding substantial progress in this area. Jon, Matt, and Tyler break down this ne ...  Show more

Why the Companies Most at Risk of Disruption Are Usually the Most Successful Ones

Disruption rarely arrives from the direction an industry expects. It came for retail from a bookseller in Seattle, for taxis from software engineers who had never driven one, and for photography from a camera company that had already invented the future but couldn't bring itself ...  Show more

Recommended Episodes

The business of not dying
Business Daily

Is longevity the next growth industry? We look at why billionaires are betting on 'rejuvenation' tech and whether any of this could help more of us live beyond 100. We meet the entrepreneurs selling 'superfoods', personalised health plans, and longevity consulting, hoping to cash ...  Show more

The $100 billion opportunity: How anti-obesity drugs are reshaping healthcare and consumer behavior
Exchanges

Goldman Sachs Research’s Chris Shibutani and Jason English explain the business and investor implications of the latest anti-obesity medications and their ripple effects in the healthcare industry and beyond. Learn more about your ad choices. Visit megaphone.fm/adchoices 

Reach Customers, Spend Less With These Expert Tips
Shopify Masters

The marketing landscape is ever changing. Digital advertising costs are rising and there are more restrictions to access customer data. How can businesses navigate these realities and reach their business goals? 

Eric Seufert, founder and partner at Heracles Capital, and ...

  Show more

Different Reads On The Consumer… And Pharma’s Obesity Drug Price Negotiations 11/5/25
CNBC's "Fast Money"

Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. Wh ...

  Show more